Achondroplasia

Rare Disease·MeSH: Achondroplasia

Prevalence

5.0 / 100K

12 drugs in development·4 companies·13 clinical trials

Drug Pipeline by Phase

Phase 3(1)

Drug	Company
lonapegsomatropin	Ascendis Pharma A/S (ASND)

Phase 2(8)

Drug	Company
bmn 111	BIOMARIN PHARMACEUTICAL INC (BMRN)
Navepegritide	Ascendis Pharma A/S (ASND)
Navepegritide	Crinetics Pharmaceuticals, Inc. (CRNX)
TYRA-200	Tyra Biosciences, Inc. (TYRA)
TYRA-300 0.125 mg/kg	Tyra Biosciences, Inc. (TYRA)
TYRA-300 0.25 mg/kg	Tyra Biosciences, Inc. (TYRA)
TYRA-300 0.375 mg/kg	Tyra Biosciences, Inc. (TYRA)
TYRA-300 0.50 mg/kg	Tyra Biosciences, Inc. (TYRA)

Phase 1(1)

Drug	Company
TYRA-300	Tyra Biosciences, Inc. (TYRA)

Phase 2/Phase 3(2)

Drug	Company
bmn 333	BIOMARIN PHARMACEUTICAL INC (BMRN)
vosoritide injection [voxzogo]	BIOMARIN PHARMACEUTICAL INC (BMRN)

BioSniper tracks 12 drugs in development for Achondroplasia across 4 companies.

There are 13 clinical trials targeting Achondroplasia tracked by BioSniper.

The estimated prevalence of Achondroplasia is approximately 5.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.